Memaxa (Memantine Hydrochloride)

Memaxa belongs to the NMDA receptor antagonist class and is used in the management of neurodegenerative dementia.

• Alzheimer’s disease (moderate to severe): improves cognition, daily functioning, and overall clinical status.
• Behavioral disturbances in Alzheimer’s disease: may reduce agitation, aggression, and related symptoms.
• Cognitive impairment associated with Alzheimer’s disease: helps maintain memory and attention functions.

• Memantine Hydrochloride acts as an uncompetitive antagonist at the NMDA (N‑methyl‑D‑aspartate) receptor. By binding within the ion channel when it is excessively open, it reduces calcium influx and limits excitotoxic neuronal damage, thereby stabilising synaptic transmission in brain regions affected by Alzheimer’s pathology.

Memaxa may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects

• Dizziness: sensation of light‑headedness or unsteadiness.
• Headache: mild to moderate pain in the head region.
• Constipation: reduced bowel movements or hard stools.
• Fatigue: feeling unusually tired or lacking energy.

Serious or Rare Side Effects

• Seizures: convulsive episodes requiring immediate medical attention.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Allergic reactions: including rash, itching, swelling, or anaphylaxis.

Before initiating Memaxa, clinicians should consider several safety aspects.

• Renal impairment: assess kidney function and adjust dose if necessary.
• Hepatic impairment: monitor liver enzymes and consider dose modification.
• Concomitant NMDA antagonists: avoid co‑administration to reduce additive CNS effects.
• History of seizures: observe closely for increased seizure activity.
• Pregnancy: safety not established; use only if potential benefit outweighs risk.
• Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Memaxa can interact with other medicines; some require avoidance while others need monitoring.

Major Interactions (Avoid)

• Amantadine: combined use may increase CNS adverse effects.
• Dextromethorphan: may potentiate neuropsychiatric side effects.
• High‑dose quinidine: can raise memantine plasma concentrations.

Moderate Interactions (Monitor Closely)

• NSAIDs: may enhance blood pressure elevation.
• Anticholinergic agents: could diminish memantine’s cognitive benefits.
• Carbamazepine: may reduce memantine levels, affecting efficacy.